 | • レポートコード：QYR2104Z1997 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、造血系疾患用治療薬・診断のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（分析装置、試薬）、用途別市場規模（学術研究所、ポイントオブケア検査、患者自己診断、バイオ医薬品産業、病院、臨床検査室）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・造血系疾患用治療薬・診断の市場動向 ・企業の競争状況、市場シェア ・造血系疾患用治療薬・診断の種類別市場規模（分析装置、試薬） ・造血系疾患用治療薬・診断の用途別市場規模（学術研究所、ポイントオブケア検査、患者自己診断、バイオ医薬品産業、病院、臨床検査室） ・造血系疾患用治療薬・診断の北米市場規模2016-2027（アメリカ、カナダ） ・造血系疾患用治療薬・診断のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・造血系疾患用治療薬・診断のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・造血系疾患用治療薬・診断の中南米市場規模2016-2027（メキシコ、ブラジル） ・造血系疾患用治療薬・診断の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Abbot、Pfizer、Amgen、Beckman Coulter、Mindray、Roche、Biorad、Eli Lilly、Sysmex、Bristol-Myers、Siemens、Horbia、Nihon Kohden） ・結論 |
Hematological disorders deal with blood related diseases and generally affect the quantity or functionality of the cells or proteins present in the blood.
Some blood disorders result in the increase of the number of cells in blood such as anemia, leukopenia while other cause the number of blood cells to decrease such as leukocytosis and thrombocytosis. The modern approach of using point of care diagnostics, cytometry techniques in hematological disorder diagnosis have outpaced the traditional methods because they can be used even in the absence of healthcare personnel and in extreme conditions.
Market Analysis and Insights: Global Drugs and Diagnostics for Hematological Disorders Market
The global Drugs and Diagnostics for Hematological Disorders market size is projected to reach US$ 127020 million by 2026, from US$ 94590 million in 2019, at a CAGR of 4.3% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Drugs and Diagnostics for Hematological Disorders market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Drugs and Diagnostics for Hematological Disorders market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Drugs and Diagnostics for Hematological Disorders market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Drugs and Diagnostics for Hematological Disorders market.
Global Drugs and Diagnostics for Hematological Disorders Scope and Market Size
Drugs and Diagnostics for Hematological Disorders market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Drugs and Diagnostics for Hematological Disorders market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Analyzers
Reagents
Segment by Application
Academic and Research Institute
Point of Care Testing
Patient Self-testing
Biopharmaceutical Industries
Hospitals
Clinical Laboratories
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Abbot
Pfizer
Amgen
Beckman Coulter
Mindray
Roche
Biorad
Eli Lilly
Sysmex
Beckman Coulter
Mindray
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs and Diagnostics for Hematological Disorders Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Analyzers
1.2.3 Reagents
1.3 Market by Application
1.3.1 Global Drugs and Diagnostics for Hematological Disorders Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Academic and Research Institute
1.3.3 Point of Care Testing
1.3.4 Patient Self-testing
1.3.5 Biopharmaceutical Industries
1.3.6 Hospitals
1.3.7 Clinical Laboratories
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Drugs and Diagnostics for Hematological Disorders Market Perspective (2016-2027)
2.2 Drugs and Diagnostics for Hematological Disorders Growth Trends by Regions
2.2.1 Drugs and Diagnostics for Hematological Disorders Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Drugs and Diagnostics for Hematological Disorders Historic Market Share by Regions (2016-2021)
2.2.3 Drugs and Diagnostics for Hematological Disorders Forecasted Market Size by Regions (2022-2027)
2.3 Drugs and Diagnostics for Hematological Disorders Industry Dynamic
2.3.1 Drugs and Diagnostics for Hematological Disorders Market Trends
2.3.2 Drugs and Diagnostics for Hematological Disorders Market Drivers
2.3.3 Drugs and Diagnostics for Hematological Disorders Market Challenges
2.3.4 Drugs and Diagnostics for Hematological Disorders Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs and Diagnostics for Hematological Disorders Players by Revenue
3.1.1 Global Top Drugs and Diagnostics for Hematological Disorders Players by Revenue (2016-2021)
3.1.2 Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Players (2016-2021)
3.2 Global Drugs and Diagnostics for Hematological Disorders Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Drugs and Diagnostics for Hematological Disorders Revenue
3.4 Global Drugs and Diagnostics for Hematological Disorders Market Concentration Ratio
3.4.1 Global Drugs and Diagnostics for Hematological Disorders Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs and Diagnostics for Hematological Disorders Revenue in 2020
3.5 Drugs and Diagnostics for Hematological Disorders Key Players Head office and Area Served
3.6 Key Players Drugs and Diagnostics for Hematological Disorders Product Solution and Service
3.7 Date of Enter into Drugs and Diagnostics for Hematological Disorders Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs and Diagnostics for Hematological Disorders Breakdown Data by Type
4.1 Global Drugs and Diagnostics for Hematological Disorders Historic Market Size by Type (2016-2021)
4.2 Global Drugs and Diagnostics for Hematological Disorders Forecasted Market Size by Type (2022-2027)
5 Drugs and Diagnostics for Hematological Disorders Breakdown Data by Application
5.1 Global Drugs and Diagnostics for Hematological Disorders Historic Market Size by Application (2016-2021)
5.2 Global Drugs and Diagnostics for Hematological Disorders Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Drugs and Diagnostics for Hematological Disorders Market Size (2016-2027)
6.2 North America Drugs and Diagnostics for Hematological Disorders Market Size by Type
6.2.1 North America Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2021)
6.2.2 North America Drugs and Diagnostics for Hematological Disorders Market Size by Type (2022-2027)
6.2.3 North America Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2027)
6.3 North America Drugs and Diagnostics for Hematological Disorders Market Size by Application
6.3.1 North America Drugs and Diagnostics for Hematological Disorders Market Size by Application (2016-2021)
6.3.2 North America Drugs and Diagnostics for Hematological Disorders Market Size by Application (2022-2027)
6.3.3 North America Drugs and Diagnostics for Hematological Disorders Market Size by Application (2016-2027)
6.4 North America Drugs and Diagnostics for Hematological Disorders Market Size by Country
6.4.1 North America Drugs and Diagnostics for Hematological Disorders Market Size by Country (2016-2021)
6.4.2 North America Drugs and Diagnostics for Hematological Disorders Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Drugs and Diagnostics for Hematological Disorders Market Size (2016-2027)
7.2 Europe Drugs and Diagnostics for Hematological Disorders Market Size by Type
7.2.1 Europe Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2021)
7.2.2 Europe Drugs and Diagnostics for Hematological Disorders Market Size by Type (2022-2027)
7.2.3 Europe Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2027)
7.3 Europe Drugs and Diagnostics for Hematological Disorders Market Size by Application
7.3.1 Europe Drugs and Diagnostics for Hematological Disorders Market Size by Application (2016-2021)
7.3.2 Europe Drugs and Diagnostics for Hematological Disorders Market Size by Application (2022-2027)
7.3.3 Europe Drugs and Diagnostics for Hematological Disorders Market Size by Application (2016-2027)
7.4 Europe Drugs and Diagnostics for Hematological Disorders Market Size by Country
7.4.1 Europe Drugs and Diagnostics for Hematological Disorders Market Size by Country (2016-2021)
7.4.2 Europe Drugs and Diagnostics for Hematological Disorders Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size (2016-2027)
8.2 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Type
8.2.1 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2027)
8.3 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Application
8.3.1 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Application (2016-2027)
8.4 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Region
8.4.1 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Drugs and Diagnostics for Hematological Disorders Market Size (2016-2027)
9.2 Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Type
9.2.1 Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2021)
9.2.2 Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Type (2022-2027)
9.2.3 Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2027)
9.3 Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Application
9.3.1 Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Application (2016-2021)
9.3.2 Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Application (2022-2027)
9.3.3 Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Application (2016-2027)
9.4 Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Country
9.4.1 Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Country (2016-2021)
9.4.2 Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size (2016-2027)
10.2 Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Type
10.2.1 Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2027)
10.3 Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Application
10.3.1 Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Application (2016-2027)
10.4 Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Country
10.4.1 Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Abbot
11.1.1 Abbot Company Details
11.1.2 Abbot Business Overview
11.1.3 Abbot Drugs and Diagnostics for Hematological Disorders Introduction
11.1.4 Abbot Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
11.1.5 Abbot Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Drugs and Diagnostics for Hematological Disorders Introduction
11.2.4 Pfizer Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Amgen
11.3.1 Amgen Company Details
11.3.2 Amgen Business Overview
11.3.3 Amgen Drugs and Diagnostics for Hematological Disorders Introduction
11.3.4 Amgen Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
11.3.5 Amgen Recent Development
11.4 Beckman Coulter
11.4.1 Beckman Coulter Company Details
11.4.2 Beckman Coulter Business Overview
11.4.3 Beckman Coulter Drugs and Diagnostics for Hematological Disorders Introduction
11.4.4 Beckman Coulter Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
11.4.5 Beckman Coulter Recent Development
11.5 Mindray
11.5.1 Mindray Company Details
11.5.2 Mindray Business Overview
11.5.3 Mindray Drugs and Diagnostics for Hematological Disorders Introduction
11.5.4 Mindray Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
11.5.5 Mindray Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche Drugs and Diagnostics for Hematological Disorders Introduction
11.6.4 Roche Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
11.6.5 Roche Recent Development
11.7 Biorad
11.7.1 Biorad Company Details
11.7.2 Biorad Business Overview
11.7.3 Biorad Drugs and Diagnostics for Hematological Disorders Introduction
11.7.4 Biorad Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
11.7.5 Biorad Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Drugs and Diagnostics for Hematological Disorders Introduction
11.8.4 Eli Lilly Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
11.8.5 Eli Lilly Recent Development
11.9 Sysmex
11.9.1 Sysmex Company Details
11.9.2 Sysmex Business Overview
11.9.3 Sysmex Drugs and Diagnostics for Hematological Disorders Introduction
11.9.4 Sysmex Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
11.9.5 Sysmex Recent Development
11.10 Bristol-Myers
11.10.1 Bristol-Myers Company Details
11.10.2 Bristol-Myers Business Overview
11.10.3 Bristol-Myers Drugs and Diagnostics for Hematological Disorders Introduction
11.10.4 Bristol-Myers Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
11.10.5 Bristol-Myers Recent Development
11.11 Siemens
11.11.1 Siemens Company Details
11.11.2 Siemens Business Overview
11.11.3 Siemens Drugs and Diagnostics for Hematological Disorders Introduction
11.11.4 Siemens Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
11.11.5 Siemens Recent Development
11.12 Horbia
11.12.1 Horbia Company Details
11.12.2 Horbia Business Overview
11.12.3 Horbia Drugs and Diagnostics for Hematological Disorders Introduction
11.12.4 Horbia Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
11.12.5 Horbia Recent Development
11.13 Nihon Kohden
11.13.1 Nihon Kohden Company Details
11.13.2 Nihon Kohden Business Overview
11.13.3 Nihon Kohden Drugs and Diagnostics for Hematological Disorders Introduction
11.13.4 Nihon Kohden Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
11.13.5 Nihon Kohden Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Drugs and Diagnostics for Hematological Disorders Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Analyzers
Table 3. Key Players of Reagents
Table 4. Global Drugs and Diagnostics for Hematological Disorders Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Drugs and Diagnostics for Hematological Disorders Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Drugs and Diagnostics for Hematological Disorders Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Drugs and Diagnostics for Hematological Disorders Market Share by Regions (2016-2021)
Table 8. Global Drugs and Diagnostics for Hematological Disorders Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Drugs and Diagnostics for Hematological Disorders Market Share by Regions (2022-2027)
Table 10. Drugs and Diagnostics for Hematological Disorders Market Trends
Table 11. Drugs and Diagnostics for Hematological Disorders Market Drivers
Table 12. Drugs and Diagnostics for Hematological Disorders Market Challenges
Table 13. Drugs and Diagnostics for Hematological Disorders Market Restraints
Table 14. Global Drugs and Diagnostics for Hematological Disorders Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Drugs and Diagnostics for Hematological Disorders Market Share by Players (2016-2021)
Table 16. Global Top Drugs and Diagnostics for Hematological Disorders Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs and Diagnostics for Hematological Disorders as of 2020)
Table 17. Ranking of Global Top Drugs and Diagnostics for Hematological Disorders Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Drugs and Diagnostics for Hematological Disorders Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Drugs and Diagnostics for Hematological Disorders Product Solution and Service
Table 21. Date of Enter into Drugs and Diagnostics for Hematological Disorders Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Type (2016-2021)
Table 25. Global Drugs and Diagnostics for Hematological Disorders Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Drugs and Diagnostics for Hematological Disorders Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Application (2016-2021)
Table 29. Global Drugs and Diagnostics for Hematological Disorders Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Drugs and Diagnostics for Hematological Disorders Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Drugs and Diagnostics for Hematological Disorders Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Drugs and Diagnostics for Hematological Disorders Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Drugs and Diagnostics for Hematological Disorders Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Drugs and Diagnostics for Hematological Disorders Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Drugs and Diagnostics for Hematological Disorders Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Drugs and Diagnostics for Hematological Disorders Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Drugs and Diagnostics for Hematological Disorders Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Drugs and Diagnostics for Hematological Disorders Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Drugs and Diagnostics for Hematological Disorders Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Drugs and Diagnostics for Hematological Disorders Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size by Country (2022-2027) & (US$ Million)
Table 61. Abbot Company Details
Table 62. Abbot Business Overview
Table 63. Abbot Drugs and Diagnostics for Hematological Disorders Product
Table 64. Abbot Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021) & (US$ Million)
Table 65. Abbot Recent Development
Table 66. Pfizer Company Details
Table 67. Pfizer Business Overview
Table 68. Pfizer Drugs and Diagnostics for Hematological Disorders Product
Table 69. Pfizer Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021) & (US$ Million)
Table 70. Pfizer Recent Development
Table 71. Amgen Company Details
Table 72. Amgen Business Overview
Table 73. Amgen Drugs and Diagnostics for Hematological Disorders Product
Table 74. Amgen Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021) & (US$ Million)
Table 75. Amgen Recent Development
Table 76. Beckman Coulter Company Details
Table 77. Beckman Coulter Business Overview
Table 78. Beckman Coulter Drugs and Diagnostics for Hematological Disorders Product
Table 79. Beckman Coulter Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021) & (US$ Million)
Table 80. Beckman Coulter Recent Development
Table 81. Mindray Company Details
Table 82. Mindray Business Overview
Table 83. Mindray Drugs and Diagnostics for Hematological Disorders Product
Table 84. Mindray Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021) & (US$ Million)
Table 85. Mindray Recent Development
Table 86. Roche Company Details
Table 87. Roche Business Overview
Table 88. Roche Drugs and Diagnostics for Hematological Disorders Product
Table 89. Roche Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021) & (US$ Million)
Table 90. Roche Recent Development
Table 91. Biorad Company Details
Table 92. Biorad Business Overview
Table 93. Biorad Drugs and Diagnostics for Hematological Disorders Product
Table 94. Biorad Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021) & (US$ Million)
Table 95. Biorad Recent Development
Table 96. Eli Lilly Company Details
Table 97. Eli Lilly Business Overview
Table 98. Eli Lilly Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021) & (US$ Million)
Table 99. Eli Lilly Recent Development
Table 100. Sysmex Company Details
Table 101. Sysmex Business Overview
Table 102. Sysmex Drugs and Diagnostics for Hematological Disorders Product
Table 103. Sysmex Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021) & (US$ Million)
Table 104. Sysmex Recent Development
Table 105. Bristol-Myers Company Details
Table 106. Bristol-Myers Business Overview
Table 107. Bristol-Myers Drugs and Diagnostics for Hematological Disorders Product
Table 108. Bristol-Myers Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021) & (US$ Million)
Table 109. Bristol-Myers Recent Development
Table 110. Siemens Company Details
Table 111. Siemens Business Overview
Table 112. Siemens Drugs and Diagnostics for Hematological Disorders Product
Table 113. Siemens Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021) & (US$ Million)
Table 114. Siemens Recent Development
Table 115. Horbia Company Details
Table 116. Horbia Business Overview
Table 117. Horbia Drugs and Diagnostics for Hematological Disorders Product
Table 118. Horbia Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021) & (US$ Million)
Table 119. Horbia Recent Development
Table 120. Nihon Kohden Company Details
Table 121. Nihon Kohden Business Overview
Table 122. Nihon Kohden Drugs and Diagnostics for Hematological Disorders Product
Table 123. Nihon Kohden Revenue in Drugs and Diagnostics for Hematological Disorders Business (2016-2021) & (US$ Million)
Table 124. Nihon Kohden Recent Development
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Drugs and Diagnostics for Hematological Disorders Market Share by Type: 2020 VS 2027
Figure 2. Analyzers Features
Figure 3. Reagents Features
Figure 4. Global Drugs and Diagnostics for Hematological Disorders Market Share by Application: 2020 VS 2027
Figure 5. Academic and Research Institute Case Studies
Figure 6. Point of Care Testing Case Studies
Figure 7. Patient Self-testing Case Studies
Figure 8. Biopharmaceutical Industries Case Studies
Figure 9. Hospitals Case Studies
Figure 10. Clinical Laboratories Case Studies
Figure 11. Drugs and Diagnostics for Hematological Disorders Report Years Considered
Figure 12. Global Drugs and Diagnostics for Hematological Disorders Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Drugs and Diagnostics for Hematological Disorders Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Drugs and Diagnostics for Hematological Disorders Market Share by Regions: 2020 VS 2027
Figure 15. Global Drugs and Diagnostics for Hematological Disorders Market Share by Regions (2022-2027)
Figure 16. Global Drugs and Diagnostics for Hematological Disorders Market Share by Players in 2020
Figure 17. Global Top Drugs and Diagnostics for Hematological Disorders Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs and Diagnostics for Hematological Disorders as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Drugs and Diagnostics for Hematological Disorders Revenue in 2020
Figure 19. Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Type (2016-2021)
Figure 20. Global Drugs and Diagnostics for Hematological Disorders Revenue Market Share by Type (2022-2027)
Figure 21. North America Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Drugs and Diagnostics for Hematological Disorders Market Share by Type (2016-2027)
Figure 23. North America Drugs and Diagnostics for Hematological Disorders Market Share by Application (2016-2027)
Figure 24. North America Drugs and Diagnostics for Hematological Disorders Market Share by Country (2016-2027)
Figure 25. United States Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Drugs and Diagnostics for Hematological Disorders Market Share by Type (2016-2027)
Figure 29. Europe Drugs and Diagnostics for Hematological Disorders Market Share by Application (2016-2027)
Figure 30. Europe Drugs and Diagnostics for Hematological Disorders Market Share by Country (2016-2027)
Figure 31. Germany Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Drugs and Diagnostics for Hematological Disorders Market Share by Region (2016-2027)
Figure 41. China Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Drugs and Diagnostics for Hematological Disorders Market Share by Type (2016-2027)
Figure 49. Latin America Drugs and Diagnostics for Hematological Disorders Market Share by Application (2016-2027)
Figure 50. Latin America Drugs and Diagnostics for Hematological Disorders Market Share by Country (2016-2027)
Figure 51. Mexico Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Share by Country (2016-2027)
Figure 57. Turkey Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Drugs and Diagnostics for Hematological Disorders Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Abbot Revenue Growth Rate in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
Figure 61. Pfizer Revenue Growth Rate in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
Figure 62. Amgen Revenue Growth Rate in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
Figure 63. Beckman Coulter Revenue Growth Rate in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
Figure 64. Mindray Revenue Growth Rate in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
Figure 65. Roche Revenue Growth Rate in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
Figure 66. Biorad Revenue Growth Rate in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
Figure 67. Eli Lilly Revenue Growth Rate in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
Figure 68. Sysmex Revenue Growth Rate in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
Figure 69. Bristol-Myers Revenue Growth Rate in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
Figure 70. Siemens Revenue Growth Rate in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
Figure 71. Horbia Revenue Growth Rate in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
Figure 72. Nihon Kohden Revenue Growth Rate in Drugs and Diagnostics for Hematological Disorders Business (2016-2021)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
世界の造血系疾患診断・治療市場規模・現状・予測（2021年-2027年） Hematology, a branch of medicine, deals with the prevention, diagnosis, and treatment of blood diseases. It includes problems associated with red blood cells (RBCs), white blood cells (WBCs), platelets, bone marrow, blood vessels, spleen, lymph nodes, and proteins involved in bleeding and clotting p…- 世界の造血系疾患診断・治療市場規模・現状・予測（2021年-2027年） Hematology, a branch of medicine, deals with the prevention, diagnosis, and treatment of blood diseases. It includes problems associated with red blood cells (RBCs), white blood cells (WBCs), platelets, bone marrow, blood vessels, spleen, lymph nodes, and proteins involved in bleeding and clotting p…
- 世界のメンデル遺伝病検査市場規模・現状・予測（2021年-2027年） The Mendelian disorder is different types of genetic disorder in humans. These genetic disorders are mainly caused by the changes or alterations in a single gene or due to the abnormalities in the genome. These conditions will be present since the child’s birth and can be predicted based on the hist…
- 世界のポイントオブケア検査市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Point of Care Testing Market The global Point of Care Testing market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report…
- 世界のポイントオブケア検査市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Point of Care Testing Market The global Point of Care Testing market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report…